Stocktoria

NeuroSense Therapeutics Ltd. NRSN

Nasdaq · stock · Pharmaceutical Preparations · website · IPO 2021-12-09

NeuroSense Therapeutics Ltd. statistics & valuation

Market cap$26.8M

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports.

Profitability & efficiency

Gross margin (%)
202320242025
Operating margin (%)
202320242025
Return on equity (%)
-395.30% 202320242025
Shares outstanding
15.4M 23.2M 32.6M 202320242025
Net debt ($)
202320242025
Share buybacks ($)
202320242025
Return on assets (%)
-317.30% -223.20% -1082.20% 202320242025
Free cash flow margin (%)
202320242025
Debt / equity (×)
202320242025
EPS ($)
-$0.74 -$0.54 -$0.44 202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023
Return on assets-1082.2%-223.2%-317.3%
Return on equity713.1%-395.3%574.6%
Current ratio0.312.210.84

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.